Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma

Herrero Martín, David; Boro, Aleksandar; Schäfer, Beat W

Abstract: A subset of paediatric sarcomas are characterized by chromosomal translocations encoding specific oncogenic transcription factors. Such fusion proteins represent tumor specific therapeutic targets although so far it has not been possible to directly inhibit their activity by small-molecule compounds. In this study, we hypothesized that screening a small-molecule library might identify already existing drugs that are able to modulate the transcriptional activity of PAX3/FOXO1, the fusion protein specifically found in the pediatric tumor alveolar rhabdomyosarcoma (aRMS). Towards this end, we established a reporter cell line based on the well characterized PAX3/FOXO1 target gene AP2ß. A library enriched in mostly FDA approved drugs was screened using specific luciferase activity as read-out and normalized for cell viability. The most effective inhibitor identified from this screen was Fenretinide. Treatment with this compound resulted in down-regulation of PAX3/FOXO1 mRNA and protein levels as well as in reduced expression of several of its direct target genes, but not of wild-type FOXO1, in a dose- and time-dependent manner. Moreover, fenretinide induced reactive oxygen species and apoptosis as shown by caspase 9 and PARP cleavage and upregulated miR-9. Importantly, it demonstrated a significant anti-tumor effect in vivo. These results are similar to earlier reports for two other pediatric tumors, namely neuroblastoma and Ewing sarcoma, where fenretinide is under clinical development. Our results suggest that fenretinide might represent a novel treatment option also for translocation-positive rhabdomyosarcoma.

DOI: https://doi.org/10.1371/journal.pone.0055072

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-84483
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at:
Herrero Martín, David; Boro, Aleksandar; Schäfer, Beat W (2013). Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma. PLoS ONE, 8(1):e55072.
DOI: https://doi.org/10.1371/journal.pone.0055072
Introduction

Prognosis of cancer patients can be strongly improved through optimization of therapeutic regimens. However, to increase survival rates it is necessary to identify and develop further alternative treatment strategies as well as to minimize treatment related side-effects, a matter of great importance for childhood cancer long-term survivors. In our studies, we use the pediatric tumor rhabdomyosarcoma (RMS) as a model system. RMS accounts for 5% to 8% of all pediatric malignancies and is the most common soft tissue sarcoma diagnosed in children [1]. Histopathologically, RMS is classified into two main subtypes, embryonal RMS (eRMS) and alveolar RMS (aRMS). eRMS represents the majority of RMS cases, ~60%, and shows a more favorable prognosis [2]. aRMS is less frequent, more aggressive, appears at unfavourable locations, frequently presents with metastasis and displays resistance to conventional chemotherapy and radiotherapy [3]. The majority of aRMS is characterized by the specific chromosomal translocation t(2;13)(q35;q14) generating the chimeric transcription factor PAX3/FOXO1 [4].

The oncogenic role of PAX3/FOXO1 depends on deregulation of PAX3 target genes as well as alteration of gene expression patterns [5], [6]. Down-regulation or inhibition of PAX3/FOXO1 inhibits proliferation and induces apoptosis in aRMS cells [7], [8], [9], hence the aRMS tumor cells become dependent on fusion protein expression. PAX3/FOXO1 transcriptional activity is subject to modulation at different molecular levels such as e.g. post-translational modifications. Phosphorylation of several serine residues in a peptide located between the two DNA-binding domains of PAX3 is required for efficient target gene activation [10]. Furthermore, stability of the fusion protein itself is subject to regulation via the proteasome pathway [11], [12]. Thus, oncogenic fusions are necessary for maintaining the malignant phenotype of aRMS which spots them as being ideal targets for development of a directed therapeutic approach.

Dose intensification of conventional multimodal chemotherapeutic regimens confers small survival benefits for RMS patients with metastatic or recurrent disease [13], [14]. Unfortunately, there are no alternative treatment strategies so far that would target tumor cells more specifically and effectively [15]. Therefore, we aimed at identifying drugs capable to modulate the transcriptional activity of PAX3/FOXO1 irrespective of their mode of action. In this study, we used a small-molecule compound library coupled with a specific reporter assay to identify fenretinide as the most promising drug inhibiting PAX3/FOXO1 activity. Fenretinide (N-(4-hydroxyphenyl) retinamide) is a synthetic vitamin A
analogue with chemopreventive [16] and known anti-tumoral activity [17]. It shows a wide range of effects in different carcinomas and importantly, is already under clinical development in several childhood malignancies [18]. Hence, our study identifies aRMS yet another pediatric tumor that might be sensitive to fenretinide treatment.

**Materials and Methods**

**Cell Lines and Reagents**

aRMS cell lines Rh4 [19] and Rh41 [20] were kindly provided by Dr. P. Houghton (Nationwide Children’s Hospital, Columbus, Ohio) and RMS13, Rh30 (aRMS), RD (eRMS) and HEK 293 cells were obtained from American Type Culture Collection (LGC Promochem, Molsheim, France). Ruch2 (eRMS, botryoid subtype) was established in our laboratory [21]. ES cell lines, TC71 and A673, were obtained from American Type Culture Collection. All cells were maintained in high glucose DMEM (Bioconcept, Allschwil, Switzerland) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, in 5% CO2 at 37°C. The small-compound library (LOPAC 1280), fenretinide, phorbol 12-myristate 13-acetate (TPA) and L-ascorbic acid were purchased from Sigma-Aldrich (Buchs, Switzerland).

**Drug-screening**

PAX3/FOXO1 luciferase reporter was based on the well characterized AP2beta promoter and generated as previously described in the pGL3 vector [10], [11]. The pGL3 enhancer vector was used as control. Vectors were electroporated individually into Rh4 cells using the AMAXA system (Lonza, Cologne, Germany) (Program O17, buffer R). Selection of stably transfected cells as pool was performed with 1 mg/ml G-418 sulfate (Promega, Wallisellen, Switzerland). 5 x 10^3 Rh4-AP2β-LF or SV40-LF cells were plated into 96 well plates and treated 24 hours later with the small-molecule compounds at a final concentration of 5 µM during 24 hours. Afterwards, luciferase activity was measured (Luciferase Assay System, Promega) according to manufacturers protocol in parallel with measuring proliferation rates (WST-1) (Roche, Basel, Switzerland) in the same wells to correct for cell viability.

**Proliferation Assay**

Twenty-four hours after seeding in 96-well plates, cells (5 x 10^3 per well) were treated with increasing concentrations of fenretinide (Sigma-Aldrich) in a final volume of 100 µL medium including 10% serum for 72 hours. WST-1 assay (Roche) was then performed according to the manufacturer’s instructions. For each concentration, the percentage of viable cells compared with control cells was plotted against the logarithm of drug concentrations. IC50 values were then calculated by nonlinear regression curve fitting using GraphPad Prism software (GraphPad Software Inc., San Diego, CA, USA).

**Quantitative Real Time PCR**

Total RNA was extracted with the RNeasy Kit (Qiagen, Hombrechtikon, Switzerland). Following DNase treatment, samples were reverse-transcribed with Oligo (dT) primers using the Omniscript Reverse Transcription Kit (Qiagen). Quantitative reverse transcription-PCR (qRT-PCR) was performed under universal cycling conditions on an ABI 7900HT instrument using commercially available target probes (PAX3, AP2β, FGFR2, FGFR4, CB1, p8 and Bcl-2) and mastermix (all from Applied Biosystems, Rotkreuz, Switzerland). Cycle threshold (Ct) values were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Experiments were performed in triplicates. Relative expression levels of the target genes among the different samples were calculated using the ΔΔCt method [22]. Mean values and standard deviations were calculated based on the results of three biological replicates at least.

**Western Blotting**

10^7 Cells were denatured in RIPA buffer supplemented with 1 mM PMSF (Roche) and Roche Complete Protease inhibitor (Roche) for 15 minutes on ice. Total cell extract was separated on 4–12% NuPAGE Bis-Tris gels (Invitrogen, Basel, Switzerland) and blotted on nitrocellulose membranes (Whatman Schleicher &

Figure 1. Schematic representation of the screening strategy based on a target gene (AP2β) driven reporter aRMS cell line.
doi:10.1371/journal.pone.0055072.g001
Blots were blocked with 5% BSA, incubated with the first antibody overnight at 4°C and with the corresponding HRP-conjugated secondary antibody for one hour at RT. Primary antibodies used were: FOXO1 (C20; 1:500) from Santa Cruz Biotechnology (Heidelberg, Germany), and Caspase 9, recognizing both the pro- and cleaved form, (1:1000) and PARP (1:1000) from Cell Signaling (Allschwil, Switzerland). β-actin antibody (A2103; 1:2000; Sigma) was used as protein loading control. Enhanced chemiluminescence detection system (SuperSignal West Femto, Pierce, Thermo Scientific, Lausanne, Switzerland) was used for signal detection.

Apoptosis Assay
Apoptosis was measured after treatment of Rh4 and RMS13 cells with fenretinide for 48 and 96 hrs. Apoptotic index was assessed by flow cytometry, using AnnexinV/FLU (BD, Schwechat, Austria). Data acquisition and analysis were done in a LSR Fortessa Cytometer (BD) using DiVa 6.x software (BD).

Reactive Oxygen Species (ROS) Generation
Rh4 and RMS13 cells were seeded and treated with fenretinide (IC50) for 24 hours. Afterwards they were incubated for one hour with the profluorescent, lipophilic dye H2-DCF-DA (dihydrodi-
After reaction with ROS, primarily hydrogen peroxide (H2O2), DCF fluorescence (max. emission 530 nm) was measured in a microplate reader (Tecan, Männedorf, Switzerland) [23].

**Analysis of miR-9 Expression**

RNA was extracted with the miRNeasy kit (Qiagen) following manufacturers protocol. Following DNase treatment, samples were reverse-transcribed using the TaqMan MicroRNA Assay Kit (Applied Biosystems). Quantitative reverse transcription-PCR (qRT-PCR) was performed on an ABI 7900HT instrument using commercially available target probe (miR-9) and mastermix (all from Applied Biosystems). Cycle threshold (Ct) values were normalized to snRNA RNU6B. Relative expression levels of miR-9 among the different samples were calculated using the ΔΔCt method [22]. Experiments were performed in triplicates. Mean values and standard deviations were calculated based on the results of two biological replicates.

**In vivo Assay**

Xenograft experiments were approved by the veterinary office of the Canton of Zurich. HEK293 GPG cells were transfected with the plasmid pLIB-LN (Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France) expressing luciferase. After collection of the retroviral supernatant, Rh4 cells were infected and selection started 48 hours later with G418 (Promega). 3×10⁶ Rh4-luc cells were re-suspended in PBS and injected s.c. into the flanks of 6 weeks old NOD/Scid Il2rg−/− (NSG) mice (Charles River, Sulzfeld, Germany). Mice bearing tumors were treated intraperitoneally after the tumor reached a volume of at least 100 mm³ with either sterile 0.9% NaCl or fenretinide at a dose of 20 mg/kg daily during two weeks. 5 mg fenretinide were dissolved in 106 µl sterile ethanol and then in 1144 µl sterile 0.9% NaCl solution to achieve a final concentration of 4 mg/ml. Tumor growth was measured every day and mice were euthanized when reaching a tumor volume of 1500 mm³. Tumor size was determined either by measuring two diameters (d1, d2) in right angles using a digital caliper and volume was calculated using the formula \( V = \frac{4}{3} \pi r^3 \), whereby \( r = \frac{d1+d2}{4} \) or by i.p. injection of D-luciferin potassium salt (Caliper Life Sciences, Oflingen, Switzerland), resuspended in sterile aqua ad injectabilia (Sintetica, Mendrisio, Switzerland) to a final concentration of 15 mg/ml at a dose of 10 µl/g body weight. Tumors were monitored in vivo after administration using an IVIS Lumina XR imaging system (Caliper Life Sciences). Total flux (photons/second) was used as the unit of measure. Every treatment group consisted of 3 mice.

**Immunohistochemistry**

Mice were sacrificed and tumors obtained by dissection fixed in PFA. Immunohistochemical analysis was done as described before [10]. H&E, Ki67 and cleaved Caspase 3 were stained. For quantitative evaluation, the number of positive cells was counted in ten randomly selected visual fields in non-necrotic areas of the tumor using Image J software. In the case of quantitative analysis of Caspase 3 positive cells, due to the presence of strong staining on the edges of the non treated tumor sections that likely represents an artefact, ten randomly selected visual fields from the inner tumor mass were included. Two-tailed, unpaired t test was used for statistical analysis. The level of significance was set at p<0.05.

**Statistical Analyses**

IC50 values were calculated by nonlinear regression curve fitting using GraphPad Prism software (GraphPad Software Inc.). Statistical significance was tested with unpaired two-tailed tests.

---

| Table 1. LOPAC small-molecule compound library screening hit list. |
| --- |
| **Compound** | **Ratio** | **Description** |
| Retinoic acid p-hydroxyanilide | 4.51 | Vitamin A acid analog |
| (+)-Quinoprole dihydrochloride | 4.29 | Dopamine receptor agonist |
| ML 10302 | 4.04 | Serotonin receptor agonist |
| Propantheline bromide | 3.95 | Muscarinic acetylcholine receptor antagonist |
| N,N,N'-Tetramethylazodicarboxamide | 3.84 | Thiol-oxidizing agent |
| Etoposide | 3.8 | Topoisomerase II inhibitor |
| L(-)-162,313 | 3.67 | Angiotensin II receptor agonist |
| 9-cyclopentyladenine | 3.43 | Adenyl cyclase inhibitor |
| R(-)-Isoproterenol (+)-bitartrate | 3.37 | Adrenoceptor agonist |
| BRL 50481 | 3.27 | Phosphodiesterase 7 inhibitor |

**Ratio**=Proliferation rate/Luciferase activity as compared to the non-treated RH4-AP2ß-LF cells (5 µM incubation for 24 hours).

**Table 2. Fenretinide affects aRMS cell proliferation in the low µM range.**

| Cell line | Fenretinide IC50a | Type |
| --- | --- | --- |
| Rh4 | 2.27 µM | Alveolar |
| Rh30 | 9.42 µM | Alveolar |
| RMS13 | 6.43 µM | Alveolar |
| Rh41 | 5.48 µM | Alveolar |
| RD | 31.48 µM | Embryonal |
| Ruch-2 | 21.21 µM | Embryonal |
| A673 | 1.09 µM | Ewing Sarcoma |
| TC71 | 21.13 µM | Ewing Sarcoma |

aIC50 values were calculated by nonlinear regression curve fitting using GraphPad Prism software.

doi:10.1371/journal.pone.0055072.t001

---

doi:10.1371/journal.pone.0055072.t002
Student’s t-tests and a p<0.05 was considered statistically significant.

Results

Fenretinide Modulates PAX3/FOXO1 Target Gene Expression

To identify compounds that might be able to modulate expression of PAX3/FOXO1 target genes either directly or indirectly, we screened a small-molecule compound library (LOPAC 1280, Sigma) which covers 1280 different drug-like and well annotated compounds including all major drug types. We used an endogenous cellular model, Rh4, which represents a PAX3/FOXO1 bearing aRMS cell with a transcription profile very similar to tumor biopsies [24] (screening strategy outlined in Figure 1). As a read-out system we simultaneously assessed cell viability together with a well established and highly sensitive luciferase reporter assay based on the AP2ß target gene promoter to monitor fusion protein activity [10], [11]. For the primary screen, Rh4-AP2ß-LF cells were treated with the compounds at a final concentration of 5 \( \mu \text{M} \) for 24 hours. Luciferase activity was measured as primary read-out and corrected for cell number measured in the same wells. Using a cut-off of 65% reduction in luciferase activity, we identified 104 compounds fulfilling all
criteria. Among them are molecules with a broad range of mechanisms such as kinases or topoisomerase II inhibitors as well as compounds related to nitric oxide. In a secondary screen, we re-measured all 104 compounds together with a SV40-driven luciferase reporter to eliminate compounds directly affecting luciferase activity. Of the remaining 52 compounds, the top-ranked 10 compounds with the highest ratio proliferation/luciferase activity were then re-tested using different concentrations (5, 1 and 0.5 \mu M) and time points (24, 48, 72 hours).

Fenretinide (retinoic acid p-hydroxyanilide) ranked as the most effective small-molecule compound affecting AP2\(\beta\)-driven luciferase activity (Table 1 and Figure 2A). Fenretinide-treated cells exerted a reduction in luciferase activity of more than 80% compared to empty vector treated cells whereas proliferation was similar for both cells at this time point (Figure 2B). Hence, fenretinide treatment provoked a non-cytotoxic repression of the PAX3/FOXO1 target gene AP2\(\beta\).

**Fenretinide Affects aRMS Cell Proliferation at the Low \mu M Range**

To investigate whether fenretinide specifically affects aRMS cells, we next treated four aRMS cell lines (Rh4, Rh41, RMS13, Rh30) with increasing concentrations of fenretinide for 72 hours to determine IC\(_{50}\) concentration in comparison to two eRMS cells (RUCH-2 and RD). Fenretinide reduced the number of viable cells in all four aRMS cell lines tested with lower IC\(_{50}\) values (IC\(_{50}\) range, 2.27–9.42 \mu M) compared to those of embryonal origin (Ruch-2, RD) that lack PAX3/FOXO1 expression (IC\(_{50}\) range, 21.21–31.48 \mu M) (Table 2). Rh4 was the aRMS cell line most sensitive to fenretinide (2.27 \mu M). As positive control, sensitivity of two E5 cell lines, A673 and TC71, was in a very similar range to what has been already reported [25]. Taken together, these results reveal a good sensitivity of translocation-positive RMS cell lines towards fenretinide treatment.

**Fenretinide Reduces Expression of PAX3/FOXO1 mRNA**

To detect early effects of fenretinide on mRNA expression levels of additional PAX3/FOXO1 target genes as well as PAX3/FOXO1 itself, we analyzed mRNA expression by qRT-PCR 24 hours after treatment with different concentrations of the drug (5, 1 and 0.5 \mu M). Fenretinide led to significant repression of both PAX3/FOXO1 expression and its target genes AP2\(\beta\) [24], fibroblast growth factor receptor 2 (FGFR2) [24], and fibroblast growth factor receptor 4 (FGFR4) [26], following a dose-dependent course in Rh4 cells. Similar observations were made for RMS13 cells (Figure 3A). Analysis after 48 hours of treatment using lower doses of fenretinide (1 and 0.5 \mu M) revealed that PAX3/FOXO1 mRNA levels together with its targets AP2\(\beta\) and FGFR4 were still repressed (Figure 3B). These findings were further corroborated on the protein level in both Rh4 and RMS13 cells (Figure 3C). They suggest that fenretinide treatment affects PAX3/FOXO1 mRNA and protein levels and that of several target genes in translocation-positive RMS cells.

Figure 4. Fenretinide induces ROS in alveolar rhabdomyosarcoma cell lines. A) Rh4 and RMS13 cells were treated for 24 hours with an IC\(_{50}\) concentration of fenretinide. H2-DCF-DA was added thereafter for 1 hour. Hydrogen peroxide was added to a final concentration of 250 \mu M to enhance ROS generation. Final concentration of TPA was 1 \mu M. Fluorescence was analyzed at 530 nm. The means ± standard deviations (error bars) of three experiments are shown. Columns, mean; bars, s.d. *** p<0.001 compared to wt. B) The effect induced by fenretinide could be blocked by a ROS inhibitor, L-ascorbic acid. Western blot analysis of Rh4 and RMS13 cells treated with IC\(_{50}\) fenretinide alone or a combination of IC\(_{50}\) fenretinide plus 100 \mu M L-ascorbic acid during different time-points (24–48–72 hours). Cells treated with IC\(_{50}\) fenretinide plus L-ascorbic acid did not show reduction in PAX3/FOXO1 levels.
doi:10.1371/journal.pone.0055072.g004
To investigate the specificity of this effect we next measured expression levels of FOXO1 in Rh4 and RMS13 cells. Using an IC50 dose of fenretinide, we did not observe any change after 24 hours and only a minor decrease after longer treatment periods (Figure 3D). In addition, the fusion negative eRMS cell line RD was treated for 24 hours with different fenretinide concentrations (5, 1 and 0.5 μM). We did not detect any change in the expression of FGFR4 in RD cells (Figure 3E). These findings suggest that fenretinide affects preferentially PAX3/FOXO1 and its gene expression signature in aRMS.

Fenretinide Induces Reactive Oxigen Species (ROS) in aRMS

To investigate whether fenretinide acts via induction of ROS production in aRMS cells, Rh4 and RMS13 cells were treated with an IC50 dose for 24 hours and incubated thereafter with the dye H2-DCF-DA to evaluate intracellular ROS levels. As a positive control for ROS generation, we stimulated cells with TPA [27]. We observed a significant increase of ROS in both Rh4 and RMS13 cells (Figure 4A). Treatment of both aRMS cell lines with L-ascorbic acid, a well-known ROS inhibitor, completely abolished repression of PAX3/FOXO1 protein levels (Figure 4B). These results suggest that fenretinide might affect aRMS cells by the same mechanism that has already been described for other pediatric tumors such as ES and neuroblastoma [25], [28], [29].

Fenretinide Provokes Apoptosis in aRMS Cells through Caspase 9 Activation and Bcl-2 Down-regulation

To investigate if the decrease in the number of viable cells after fenretinide treatment was due to apoptosis induction, we performed flow cytometry analysis with combined Annexin V and PI staining. We observed a dose-dependent increase in the number of cells within the apoptotic fraction (sub-G1) in both aRMS cells. For example in Rh4 cells treated with fenretinide at IC50 for 48 hours, the apoptotic index increased to <30% and could be partially blocked by addition of L-ascorbic acid. Similar observations were made with RMS13 cells (Figure 5A). Also, induction of pro-caspase 9 and PARP cleavage
in a dose and time-dependent manner was observed (Figure 5B). Next, we assessed the mRNA expression levels of the anti-apoptotic protein Bcl-2 by qRT–PCR. Fenretinide prompted a marked decrease in Bcl-2 levels particularly after 24 hour exposure in both aRMS cell lines (Figure 5C). Collectively, these results suggest that fenretinide induces apoptosis in aRMS cells via caspase 9 activation and a marked decrease in Bcl-2 levels.

**Fenretinide Induces miR-9 Expression**

It has been shown previously that fenretinide is able to increase miR-9 levels in human retinal pigment epithelial cells [30]. Hence, we analyzed expression of miR-9 after two low dose (0.5 and 1 μM) treatment at two different time points (24 and 72 hours) by qRT-PCR. Significant up-regulation of miR-9 was seen in both aRMS cell lines (Figure 6A, B).

**Fenretinide Delays Tumor Growth in vivo**

Finally, we used an aRMS xenograft mouse model generated by subcutaneous injection of Rh4 cells engineered to constitutively express luciferase into immunocompromised NOD/ScidIg2−/− mice to analyze the effects of fenretinide in vivo. Treatment with fenretinide at a dose of 20 mg/kg daily during two weeks significantly slowed down tumor growth compared to control mice both when measuring tumor volume (Figure 7A, left) as well as luciferase activity (Figure 7B, right). To further characterize the effect of fenretinide, tumors were isolated, paraffin-embedded and immunohistochemically stained with the proliferation marker Ki67 and activated caspase 3. As shown in Figure 7B, the number of both Ki-67 and caspase 3 positive cells was clearly reduced in the treated tumors, with large areas without positive cells. Quantitative analysis revealed that the reduction was statistically significant. We did also not observe any adverse physiological effects in the treated mice. Hence, fenretinide displays an anti-tumorigenic effect also in vivo.

**Discussion and Conclusion**

aRMS is in urgent need of new therapeutic approaches as resistance to current chemotherapeutic regimens is unfortunately common [31] and relapsed and metastatic patients show a very poor prognosis [13], [32]. In this study, we have used a library of 1280 well characterized small-molecule compounds together with...
Figure 7. Fenretinide delays tumor growth in vivo. Growth rate of Rh4 xenograft tumors in NOD/ScidI2tg^{−/−} mice (n = 3) treated with sterile 0.9% NaCl (control) or fenretinide (treated). Left: tumor volume was determined using a calliper, Right: tumor volumes determined according to luminescence values measured by IVIS Lumina XR imaging system (Caliper Life Sciences). B) Immunohistological staining of Ki67 (left) and activated caspase 3 (right) of Rh4 xenograft tumor sections treated with sterile 0.9% NaCl or fenretinide. C) Quantification of Ki67 and activated caspase 3 positive cells counted per field using Image J software in Rh4 sections of tumors treated with sterile 0.9% NaCl or fenretinide. Columns: mean; bars, s.d. *p<0.05 compared to control mice.

doi:10.1371/journal.pone.0055072.g007
an endogenous aRMS cellular model (Rh4) to screen for the most active compounds. We have identified fenretinide as the most effective agent reducing PAX3-FOXO1 levels in vitro and decreasing tumor growth in vivo. While most of the fenretinide-treated cells remained alive after short exposure, they already displayed a marked reduction in AP2β-driven luciferase activity (up to 80% decrease) as compared to non-treated cells. Even more striking, fenretinide treatment resulted in a significant reduction of PAX3-FOXO1 mRNA and protein levels, and consequently affected expression of its target genes. To our knowledge, this is the first report of fenretinide activity in aRMS.

Fenretinide (N-(4-hydroxyphenyl)retinamide) is a synthetic retinoid derivative that holds potential both as anticancer and chemopreventive drug. It is well tolerated both in adult and paediatric patients [33]. Moreover, the drug demonstrated activity both in vitro and in vivo against a wide range of tumors [34], [35] including childhood neuroblastoma and ES [36], [37]. Hence, several clinical trials with fenretinide in paediatric cancer patients are ongoing [18], [38]. Retinoic acid (RA) and derivatives such as ATRA (all-trans-retinoic acid) and CRA (13-cis retinoic acid) have demonstrated effects inhibiting growth and promoting differentiation of some, but not all RMS cell lines [39], [40]. We have shown that fenretinide was able to inhibit the growth of aRMS cells at low μM concentration (Rh4 IC50 2.27 μM and RMS13 IC50 6 μM). aRMS cells were more sensitive to fenretinide than translocation-negative eRMS cell lines. These IC50 values are very similar to the ones already described in other paediatric neoplasias such as rhabdoid tumors [41] and only slightly higher than in ES cells [25].

Fenretinide alters the PAX3/FOXO1 dependent transcriptional program since it represses PAX3/FOXO1 at both mRNA and protein levels. Consequently, also well-defined targets such as AP2β, FGFR2 or FGFR4 [24], [26] are repressed. Among these, FGFR4 is known to play an important role in aRMS since activating mutations in its tyrosine kinase domain have been reported in a subset of primary tumors associated with an enhanced metastatic phenotype in xenografts [42]. AP2β has been validated as direct target gene mediating the anti-apoptotic and proliferative function of PAX3/FOXO1 and FGFR2 is part of the PAX3/FOXO1 in vivo target gene signature [24]. In Rh4 and RMS13 cells levels of FGFR4; AP2β and FGFR2 are diminished by fenretinide using lower doses such as 0.5 and 1 μM and they remained repressed for 72 hours of treatment. Fenretinide also reduced protein levels of PAX3/FOXO1 in both cell lines and as expected, FGFR4 protein levels were also found to be repressed (data not shown). Fenretinide treatment also down-regulated CB1 (data not shown), another direct target gene of PAX3/FOXO1 [6], confirming an inverse correlation between these two genes that was reported previously [43]. Fenretinide modified FOXO1 levels only minor in aRMS cells and FGFR4 expression was not changed in eRMS cell line RD that lacks the fusion protein. Thus, fenretinide affected PAX3/FOXO1 gene expression signature preferentially in translocation-positive RMS cells as these effects can not be observed in translocation-negative RMS cell lines. We conclude that fenretinide reduces PAX3/FOXO1 levels and most importantly PAX3/FOXO1 transcriptional activity, at least at the level of target gene expression. However, the mechanisms leading to reduction in PAX3/FOXO1 mRNA levels remain to be investigated further. Since very little is known about transcriptional regulation of PAX3/FOXO1 in aRMS cells, identification of fenretinide provides a first important tool the address this issue in the future.

Fenretinide induced apoptosis in both aRMS cell lines similar to what has already been described in many other tumors [17].
Acknowledgments

The authors would like to thank Dieter Pritz for his help in FACS analysis and to Stephan Niedan for his assistance in figure preparation.

Author Contributions

Conceived and designed the experiments: DHM BWS. Performed the experiments: DHM AB. Analyzed the data: DHM AB. Wrote the paper: DHM BWS.

References

1. O’Brien D, Jacob AG, Qualman SJ, Chandler DS (2012) Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol 27: 13–22.

2. Koscielniak E, Harms D, Henze G, Juergens H, Gadner H, et al. (1999) Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230–235.

3. Kraschnewski L, Hoefer D, Henze G, Jurgens H, Gadner H, et al. (1999) Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86. J Clin Oncol 17: 3706–3719.

4. Meier WH, Spunt SL (2004) Soft tissue sarcomas of childhood. Cancer Treat Rev 30: 269–290.

5. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ 3rd, et al. (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcoma is a more potent transcriptional activator than PAX3. Mol Cell Biol 15: 1522–1535.

6. Begum S, Emani N, Cheung A, Wilkins O, Der S, et al. (2005) Cell-type-specific regulation of distinct sets of gene targets by Pax3 and PAX3/FKHR. Oncogene 24: 1860–1872.

7. Kikuchi K, Tsuchiya K, Otate O, Gotobi T, Tamura S, et al. (2005) Effects of PAX3-FKHR on malignant phenotypes in alveolar rhabdomyosarcoma. Biochem Biophys Res Commun 365: 568–574.

8. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, et al. (2008) Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res 68: 5003–5014.

9. Bernasconi M, Rempiis A, Fredericks WJ, Rauscher III FJ, Schafer BW (1996) Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX3/FKHR. Cancer Res 56: 13164–13169.

10. Amstutz R, Wachtel M, Troxler H, Kleinert P, Ebauer M, et al. (2008) Phosphorylation regulates transcriptional activity of PAX3/FKHR and reveals novel therapeutic possibilities. Cancer Res 68: 3767–3776.

11. Hecker RM, Amstutz RA, Wachtel M, Walter D, Niggli FK, et al. (2010) p21 inhibition of the survival function of PAX3/FKHR. Oncogene 29: 3942–3952.

12. Rede W, Buyer A, Caverne WK, Arden KC (2006) Guilt by association: PAX3-FKHR. Cell Cycle 7: 837–841.

13. Pappo AS, Anderson JR, Crist WM, Wharam MD, Brentfield PP, et al. (1999) Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J Clin Oncol 17: 3467–3493.

14. Smith LM, Anderson JR, Qualman SJ, Crist WM, Paedon CN, et al. (2007) Which patients with microscopic disease and rhabdomyosarcoma experience relapse after therapy? A report from the soft tissue sarcoma committee of the children’s oncology group. J Clin Oncol 19: 4038–4046.

15. Wachtel M, Schafer BW (2010) Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36: 318–327.

16. Zelone AL, Millevoi LM, Crowell J, Siganian G, Higley H (2004) Fenretinide: a prototype cancer prevention drug. Expert Opin Investig Drugs 12: 1829–1842.

17. Hail N Jr, Kim HJ, Lotan R (2006) Mechanisms of fenretinide-induced apoptosis. Apoptosis 11: 1677–1694.

18. Villablanca JG, London WB, Narang J, McGrady P, Ames MM, et al. (2011) Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/ Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children’s Oncology Group. Clin Cancer Res 17: 6588–6596.

19. Houghton JA, Houghton PJ, Webbler BL (1982) Growth and characterization of childhood rhabdomyosarcomas as xenografts. J Natl Cancer Inst 68: 437–443.

20. Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, et al. (2007) The pediatric preclinical testing program: design of models and early testing results. Pediatric Blood Cancer 49: 929–940.

21. Scholl FA, Betts DR, Nigglì FK, Schafer BW (2000) Molecular features of a human rhabdomyosarcoma cell line with spontaneous metastatic progression. Br J Cancer 82: 1239–1245.

22. Pluif MW (2003) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.

23. Rosenkranz AR, Schmidkloth J, Stuhlmeier KM, Chen W, Knapp W, et al. (1992) A microplate assay for the detection of oxidative products using 2,7'-dichlorofluorescein-diacetate. J Immunol Methods 160: 39–45.

24. Elsner M, Wachtel M, Nigglì FK, Schafer BW (2007) Comparative expression profiling identifies an in vivo target gene signature with TFP2B as a mediator of the survival function of PAX3/FKHR. Oncogene 26: 7267–7281.
Garzon R, Marcucci G, Croce CM (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775–789.

Selcuklu SD, Donoghue MT, Rehmet K, de Souza Gomes M, Fort A, et al. (2012) MicroRNA-9 inhibition of cell proliferation and identification of novel miR-9 targets by transcriptome profiling in breast cancer cells. J Biol Chem 287: 29516–29528.

Ferretti E, De Smale E, Po A, Di Marcotullio L, Tosi E, et al. (2009) MicroRNA profiling in human medulloblastoma. Int J Cancer 124: 568–577.

Zong Z, Li N, Liang S, Huang Q, Guo K, et al. (2010) Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 285: 41961–41971.

Karmakar S, Choudhary SR, Banik NL, Ray SK (2011) N-(4-Hydroxyphenyl)retinamide Potentiated Anti-tumor Efficacy of Genistein in Human Ewing’s Sarcoma Xenografts. World J Oncol 2: 53–63.

Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP (2008) Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. J Natl Cancer Inst 100: 580–595.

White DE, Burchill SA (2010) Fenretinide-dependent upregulation of death receptors through ASK1 and p38α enhances death receptor ligand-induced cell death in Ewing’s sarcoma family of tumours. Br J Cancer 103: 1380–1390.